journal
MENU ▼
Read by QxMD icon Read
search

Journal of the National Comprehensive Cancer Network: JNCCN

journal
https://www.readbyqxmd.com/read/29295884/pregnancy-screening-in-patients-with-cancer
#1
Annika M Gustafson, Deborah J Goldfrank, William A Dunson, Daniel L Mulkerin, Rebecca L Caires, Keith D Eaton
No abstract text is available yet for this article.
January 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29295883/adolescent-and-young-adult-oncology-version-2-2018-nccn-clinical-practice-guidelines-in-oncology
#2
Peter F Coccia, Alberto S Pappo, Lynda Beaupin, Virginia F Borges, Scott C Borinstein, Rashmi Chugh, Shira Dinner, Jeanelle Folbrecht, A Lindsay Frazier, Robert Goldsby, Alexandra Gubin, Robert Hayashi, Mary S Huang, Michael P Link, John A Livingston, Yousif Matloub, Frederick Millard, Kevin C Oeffinger, Diane Puccetti, Damon Reed, Steven Robinson, Abby R Rosenberg, Tara Sanft, Holly L Spraker-Perlman, Margaret von Mehren, Daniel S Wechsler, Kimberly F Whelan, Nicholas Yeager, Lisa A Gurski, Dorothy A Shead
This selection from the NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology focuses on treatment and management considerations for AYA patients with cancer. Compared with older adults with cancer, AYA patients have unique needs regarding treatment, fertility counseling, psychosocial and behavioral issues, and supportive care services. The complete version of the NCCN Guidelines for AYA Oncology addresses additional aspects of caring for AYA patients, including risk factors, screening, diagnosis, and survivorship...
January 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29295882/chemoradiotherapy-versus-chemotherapy-alone-for-unresected-nonmetastatic-gallbladder-cancer-national-practice-patterns-and-outcomes
#3
Vivek Verma, Swati M Surkar, Eric D Brooks, Charles B Simone, Chi Lin
Purpose: Current guidelines recommend chemotherapy (CT) with or without radiotherapy for unresected nonmetastatic gallbladder cancer (GC), with little consensus. However, several small-volume, single-institution studies have documented the efficacy of local therapy for this population. This is the largest study to date evaluating outcomes of chemoradiotherapy (CRT) versus CT alone in unresected nonmetastatic GC. Methods: The National Cancer Database was queried for primary GC cases (2004-2013) receiving CT alone or CRT...
January 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29295881/frequency-morbidity-and-mortality-of-bone-metastases-in-advanced-hepatocellular-carcinoma
#4
James J Harding, Ghaith Abu-Zeinah, Joanne F Chou, Dwight Hall Owen, Michele Ly, Maeve Aine Lowery, Marinela Capanu, Richard Do, Nancy E Kemeny, Eileen M O'Reilly, Leonard B Saltz, Ghassan K Abou-Alfa
Background: Bone metastases are common in hepatocellular carcinoma (HCC), but their incidence, morbidity, and mortality are not well defined. Methods: The Memorial Sloan Kettering Cancer Center database was queried for all patients with HCC and metastases seen from 2002 to 2014. The prevalence of bone metastasis was determined and cumulative incidence function was used to estimate the probability of developing a bone metastasis. Regression models were created to identify risk factors for osseous metastasis...
January 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29295880/evaluation-of-ajcc-and-an-alternative-tumor-classification-system-for-primary-vulvar-squamous-cell-carcinoma
#5
Sarah T Le, Pritesh S Karia, Beverley J Vollenhoven, Robert J Besaw, Colleen M Feltmate, Chrysalyne D Schmults
Background: Currently, no studies have attempted to validate the AJCC tumor (T) class for vulvar cancer or examine its performance via clinical data. The goal of this study was to identify risk factors associated with poor outcomes in vulvar squamous cell carcinoma (vSCC) and compare prognostic discrimination of these outcomes between the AJCC T-classification system and the newly developed Brigham and Women's Vulvar Tumor Classification system (BWVTC). Methods: A 15-year, 2-center retrospective cohort study of primary vSCCs (N=226) was undertaken...
January 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29295879/the-right-place-at-the-right-time-medical-oncology-outpatients-perceptions-of-location-of-end-of-life-care
#6
Amy Waller, Rob Sanson-Fisher, Nicholas Zdenkowski, Charles Douglas, Alix Hall, Justin Walsh
Background: Helping people achieve their preferred location of care is an important indicator of quality end-of-life (EOL) care. Using a sample of Australian medical oncology outpatients, this study examined (1) their preferred location of EOL care; (2) their perceived benefits and worries of receiving care in that location; (3) the percentage who had discussed preferences with their doctor and/or support person; and (4) whether they wanted their doctor to ask them where they wanted to die. Methods: Adults with a confirmed diagnosis of cancer were approached between September 2015 and January 2016 in the waiting room of an Australian oncology outpatient clinic...
January 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29295878/understanding-comorbidity-profiles-and-their-effect-on-treatment-and-survival-in-patients-with-colorectal-cancer
#7
Erin E Hahn, Michael K Gould, Corrine E Munoz-Plaza, Janet S Lee, Carla Parry, Ernest Shen
Background: Patients with colorectal cancer (CRC) commonly present at an older age with multiple comorbid conditions and complex care needs at the time of diagnosis. Clusters of comorbid conditions, or profiles, have not been systematically identified in this patient population. This study aimed to identify clinically distinct comorbidity profiles in a large sample of patients with CRC from an integrated healthcare system, and to examine the effect of comorbidity profiles on treatment and survival. Methods: In this retrospective cohort study, we used latent class analysis (LCA) to identify comorbidity profiles in a sample of 7,803 patients with CRC diagnosed between 2008 and 2013...
January 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29295877/nccn-guidelines-insights-multiple-myeloma-version-3-2018
#8
Shaji K Kumar, Natalie S Callander, Melissa Alsina, Djordje Atanackovic, J Sybil Biermann, Jorge Castillo, Jason C Chandler, Caitlin Costello, Matthew Faiman, Henry C Fung, Kelly Godby, Craig Hofmeister, Leona Holmberg, Sarah Holstein, Carol Ann Huff, Yubin Kang, Adetola Kassim, Michaela Liedtke, Ehsan Malek, Thomas Martin, Vishala T Neppalli, James Omel, Noopur Raje, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Donna Weber, Joachim Yahalom, Rashmi Kumar, Dorothy A Shead
The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, evaluation, treatment, including supportive-care, and follow-up for patients with myeloma. These NCCN Guidelines Insights highlight the important updates/changes specific to the myeloma therapy options in the 2018 version of the NCCN Guidelines.
January 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29295876/rapid-clinical-and-radiographic-response-with-combined-dabrafenib-and-trametinib-in-adults-with-braf-mutated-high-grade-glioma
#9
Tanner M Johanns, Cole J Ferguson, Patrick M Grierson, Sonika Dahiya, George Ansstas
BRAF V600E mutations have been successfully treated with targeted therapy in melanoma, non-small cell lung cancer, and thyroid cancer. Interestingly, these mutations have also been identified in a subset of pediatric and adult brain tumors, with several cases reportedly responding to targeted therapy. However, these reports have been limited to single-agent BRAF inhibitor therapy and recurrent disease. Herein, we report dramatic clinical and radiographic responses to combination dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) in 2 adults with high-grade gliomas (HGGs), with 1 patient treated in the first-line setting...
January 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29295875/your-genes-one-size-doesn-t-fit-all
#10
Mary E Freivogel, Stephanie A Cohen
No abstract text is available yet for this article.
January 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29295874/revisiting-new-year-s-resolutions
#11
Margaret Tempero
No abstract text is available yet for this article.
January 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29223995/reviewer-page
#12
(no author information available yet)
No abstract text is available yet for this article.
December 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29223993/disparities-in-adjuvant-endocrine-therapy
#13
Elizabeth J Cathcart-Rake, Kathryn J Ruddy
No abstract text is available yet for this article.
December 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29223992/controversies-regarding-use-of-myeloid-growth-factors-in-leukemia
#14
REVIEW
Jacqueline N Poston, Pamela S Becker
This review focuses on the data supporting the use of myeloid growth factors (MGFs) in patients being treated for acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, and hairy cell leukemia, for which neutropenia is a common complication of treatment. However, due to the lack of randomized trial data or conflicting results of clinical studies, comprehensive guidelines have been difficult to formulate. Moreover, to date, these diagnoses have not been addressed in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for MGFs...
December 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29223991/a-patient-risk-model-of-chemotherapy-induced-febrile-neutropenia-lessons-learned-from-the-anc-study-group
#15
REVIEW
Gary H Lyman, Marek S Poniewierski
Neutropenia and its complications, including febrile neutropenia (FN), represent major toxicities associated with cancer chemotherapy, resulting in considerable morbidity, mortality, and costs. The myeloid growth factors such as granulocyte colony-stimulating factor (G-CSF) have been shown to reduce the risk of neutropenia complications while enabling safe and effective chemotherapy dose intensity. Concerns about the high costs of these agents along with limited physician adherence to clinical practice guidelines, resulting in both overuse and underuse, has stimulated interest in models for individual patient risk assessment to guide appropriate use of G-CSF...
December 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29223990/myeloid-growth-factors-version-2-2017-nccn-clinical-practice-guidelines-in-oncology
#16
Jeffrey Crawford, Pamela Sue Becker, James O Armitage, Douglas W Blayney, Julio Chavez, Peter Curtin, Shira Dinner, Thomas Fynan, Ivana Gojo, Elizabeth A Griffiths, Shannon Hough, Dwight D Kloth, David J Kuter, Gary H Lyman, Mary Mably, Sudipto Mukherjee, Shiven Patel, Lia E Perez, Adam Poust, Raajit Rampal, Vivek Roy, Hope S Rugo, Ayman A Saad, Lee S Schwartzberg, Sepideh Shayani, Mahsa Talbott, Saroj Vadhan-Raj, Sumithira Vasu, Martha Wadleigh, Peter Westervelt, Jennifer L Burns, Lenora Pluchino
Myeloid growth factors (MGFs) are given as supportive care to patients receiving myelosuppressive chemotherapy to reduce the incidence of neutropenia. This selection from the NCCN Guidelines for MGFs focuses on the evaluation of regimen- and patient-specific risk factors for the development of febrile neutropenia (FN), the prophylactic use of MGFs for the prevention of chemotherapy-induced FN, and assessing the risks and benefits of MGF use in clinical practice.
December 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29223989/geographic-variation-of-adjuvant-breast-cancer-therapy-initiation-in-the-united-states-lessons-from-medicare-part-d
#17
John A Charlson, Emily L McGinley, Ann B Nattinger, Joan M Neuner, Liliana E Pezzin
Background: Drug utilization under Medicare Part D varies significantly by geographic region. This study examined the extent to which geographic variation in Part D plan characteristics contributes to the variation in choice of initial endocrine therapy agent among women with incident breast cancer. Methods: Two-stage multivariate regression analyses were applied to the 16,541 women identified from Medicare claims as having incident breast cancer in 2006-2007. The first stage determined the effect of state of residence on the probability of having an aromatase inhibitor (AI), as opposed to tamoxifen, as initial endocrine therapy...
December 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29223988/prevalence-of-physical-problems-detected-by-the-distress-thermometer-and-problem-list-in-patients-with-myeloproliferative-disorders
#18
Daniel C McFarland, Kelly M Shaffer, Heather Polizzi, John Mascarenhas, Marina Kremyanskaya, Jimmie Holland, Ronald Hoffman
Background: Patients with myeloproliferative neoplasms (MPNs) can have a severe physical symptom burden over an extended disease trajectory that contributes to decreased quality of life. Few studies, however, have characterized which patients most frequently consider physical symptoms a problem. This study describes the physical symptoms of patients with MPNs and the relationship of these symptoms to patient characteristics. Methods: Patients with MPNs (N=117) completed questionnaires in a dedicated academic medical center MPN clinic...
December 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29223987/radiosurgery-for-brain-metastases-changing-practice-patterns-and-disparities-in-the-united-states
#19
Benjamin H Kann, Henry S Park, Skyler B Johnson, Veronica L Chiang, James B Yu
Background: Management of brain metastases typically includes radiotherapy (RT) with conventional fractionation and/or stereotactic radiosurgery (SRS). However, optimal indications and practice patterns for SRS remain unclear. We sought to evaluate national practice patterns for patients with metastatic disease receiving brain RT. Methods: We queried the National Cancer Data Base (NCDB) for patients diagnosed with metastatic non-small cell lung cancer, breast cancer, colorectal cancer, or melanoma from 2004 to 2014 who received upfront brain RT...
December 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29223986/kras-testing-tumor-location-and-survival-in-patients-with-stage-iv-colorectal-cancer-seer-2010-2013
#20
Mary E Charlton, Amanda R Kahl, Alissa A Greenbaum, Jordan J Karlitz, Chi Lin, Charles F Lynch, Vivien W Chen
Purpose:KRAS mutations and tumor location have been associated with response to targeted therapy among patients with stage IV colorectal cancer (CRC) in various trials. This study performed the first population-based examination of associations between KRAS mutations, tumor location, and survival, and assessed factors associated with documented KRAS testing. Methods: Patients with stage IV adenocarcinoma of the colon/rectum diagnosed from 2010 to 2013 were extracted from SEER data. Analyses of patient characteristics, KRAS testing, and tumor location were conducted using logistic regression...
December 2017: Journal of the National Comprehensive Cancer Network: JNCCN
journal
journal
40348
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"